Ashley Dalton

I will come back to the hon. Gentleman on that, but I thank him for raising the issue. We have also talked a lot about what underpins this topic: research and innovation, and my hon. Friend the Member for Stafford raised that point in particular. We are taking strides in vital research. By the spring, the NIHR expects to launch its sex and gender policy, which will ensure that research is designed, conducted and reported in a way that accounts for sex and gender—a point raised by the hon. Member for Canterbury. That will support our understanding of how women might be impacted differently by health conditions. The hon. Member for Bath (Wera Hobhouse) talked about eating disorders and also about breast cancer, which a number of people raised. As I am sure the hon. Lady appreciates, that issue is important to me, as I was diagnosed with a breast cancer when I was under the age of 42. It is an important issue. Health in the workplace continues to be an important issue for us, and we are dealing with that through our make work pay strategy and the Employment Rights Bill, which will set out some of those steps, including support for women experiencing menopause in the workplace. On sodium valproate and pelvic mesh, the Cumberlege review made nine recommendations, of which the then Government accepted seven. I can confirm that the national pause remains in place.